Overview

Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)

Status:
Unknown status

Trial end date:
2020-03-01

Target enrollment:

Participant gender:

Summary

The main purpose of the study is to determine the antiviral efficacy and evaluate the safety and tolerability of sofosbuvir/ velpatasvir (SOF/VEL) and sofosbuvir/ velpatasvir/ voxilaprevir (SOF/VEL/VOX) used to treat individuals with chronic hepatitis C virus infection in Rwanda adults.

Phase:

Phase 4

Details

Lead Sponsor:

Partners in Health

Treatments:

Velpatasvir